Loading...
•
Dec 31, 2022
Longeveron Q4 2022 Earnings Report
Reported financial results and corporate update for the fourth quarter and full year of 2022.
Key Takeaways
Longeveron reported fourth quarter revenue of $0.1 million and a net loss of $4.5 million. The company's cash and short-term investments totaled $19.6 million. They believe that existing cash and short-term investments will be sufficient to cover expenses and capital requirements into the first half of 2024.
Longeveron executed on multiple key milestones, advancing Lomecel-BTM for multiple indications in 2022.
Full data from the ELPIS I trial of Lomecel-BTM for infants with HLHS was published in European Heart Journal Open.
Progress was made with the Japan Aging-Related Phase 2 study.
First patient to be randomized in Japan Aging-Related Phase 2 study in Q1.
Forward Guidance
Based on the Company’s current operating plan and financial resources, they believe that their existing cash and short-term investments will be sufficient to cover expenses and capital requirements into first half of 2024.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...